The major understanding of the function of the TSC1/TSC2 protein complex as a critical regulator of the Rheb GTPase and thereby mTORC1 activity in recent years has led to considerable enthusiasm about the potential efficiency of rapamycin and other mTORC1 inhibitors as therapy for these TSC tumors [7]. The gene discussed is RHEB; the disease is tuberous sclerosis.